Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

November 09, 2017

WhatsApp Enables Swift Diagnosis of STEMI and Cath Lab Activation

News Daily News

WhatsApp Enables Swift Diagnosis of STEMI and Cath Lab Activation

Yael L. Maxwell

October 27, 2017

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

September 08, 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

September 07, 2017

LAACS: Surgical Closure of the Left Atrial Appendage Shows Promise

News Conference News ESC 2017

LAACS: Surgical Closure of the Left Atrial Appendage Shows Promise

September 04, 2017

Clinical Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

News Conference News ESC 2017

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

Yael L. Maxwell

September 01, 2017

TCTMD’s Top 10 Most Popular Stories for August 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

August 31, 2017

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

News Conference News ESC 2017

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

Michael O'Riordan

August 31, 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

News Conference News ESC 2017

IMPACT-AF: Education, Feedback Boost Oral Anticoagulation Use for A-fib

August 30, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

PURE Investigators: Rethink Diet Guidance to Plug More Fats, Fewer Carbs

News Conference News ESC 2017

PURE Investigators: Rethink Diet Guidance to Plug More Fats, Fewer Carbs

August 29, 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

News Conference News ESC 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

August 29, 2017

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

News Conference News ESC 2017

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

Michael O'Riordan

August 29, 2017

News Industry News

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

August 28, 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

August 27, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.